Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-926-7655
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees5
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions
What is Dare Bioscience's stock symbol?
Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."
How were Dare Bioscience's earnings last quarter?
Dare Bioscience Inc (NASDAQ:DARE) issued its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.09. View Dare Bioscience's Earnings History.
When is Dare Bioscience's next earnings date?
What price target have analysts set for DARE?
2 brokers have issued 1-year price objectives for Dare Bioscience's shares. Their predictions range from $3.00 to $3.00. On average, they expect Dare Bioscience's stock price to reach $3.00 in the next year. This suggests a possible upside of 277.3% from the stock's current price. View Analyst Price Targets for Dare Bioscience.
What is the consensus analysts' recommendation for Dare Bioscience?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.
Has Dare Bioscience been receiving favorable news coverage?
Headlines about DARE stock have trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dare Bioscience earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Dare Bioscience.
Are investors shorting Dare Bioscience?
Dare Bioscience saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 621,700 shares, a drop of 12.6% from the August 30th total of 711,600 shares. Based on an average trading volume of 113,300 shares, the days-to-cover ratio is presently 5.5 days. Approximately 4.6% of the shares of the company are short sold. View Dare Bioscience's Current Options Chain.
Who are some of Dare Bioscience's key competitors?
Some companies that are related to Dare Bioscience include Pharmaxis (PXSLY), ASLAN PHARMACEU/ADR (ASLN), Iterum Therapeutics (ITRM), Eyenovia (EYEN), Melinta Therapeutics (MLNT), Oramed Pharmaceuticals (ORMP), Arbutus Biopharma (ABUS), Spring Bank Pharmaceuticals (SBPH), SUMMIT THERAPEU/S (SMMT), Agile Therapeutics (AGRX), Aridis Pharmaceuticals (ARDS), Vistagen Therapeutics (VTGN), ESSA Pharma (EPIX), Tiziana Life Sciences (TLSA) and Moleculin Biotech (MBRX).
What other stocks do shareholders of Dare Bioscience own?
Who are Dare Bioscience's key executives?
Dare Bioscience's management team includes the folowing people:
- Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)
- Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)
- Mr. Mark Walters, VP of Operations (Age 64)
- Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 43)
- Dr. David Friend, Chief Scientific Officer
How do I buy shares of Dare Bioscience?
Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Dare Bioscience's stock price today?
One share of DARE stock can currently be purchased for approximately $0.80.
How big of a company is Dare Bioscience?
Dare Bioscience has a market capitalization of $13.26 million. The biotechnology company earns $-16,740,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.View Additional Information About Dare Bioscience.
What is Dare Bioscience's official website?
How can I contact Dare Bioscience?
Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]
MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
